Skip to main content

Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma.

Publication ,  Journal Article
Tarhini, AA; Hanayneh, WB; Powers, JJ; Segura, CMM; Conejo-Garcia, JR; Lam, CA; Hakam, A; Hoffman, MS
Published in: Front Oncol
2022

Optimal management of locally advanced vaginal mucosal melanoma is poorly understood because of its rarity and unique biology. Patients have a poor prognosis despite aggressive management approaches including pelvic exenteration and adjuvant radiation that carry major morbidities. We report a case of a patient in early 40's who experienced complete pathologic response and organ preservation following immunotherapy consisting of 3 cycles of ipilimumab and nivolumab. Treatment was complicated by a high-grade immune mediated hepatitis that eventually resolved with immunosuppressive therapy. Immune monitoring studies utilizing vaginal tumor biopsies showed evidence of enhanced infiltration by CD3+/CD8+ cytotoxic T-cells and increased expression of MHC-I/PD-L1 within the tumor microenvironment following immunotherapy. The patient continues to be without evidence of disease recurrence by radiologic and gynecologic examinations with more than 2 years of follow up from the time of immunotherapy initiation. To our knowledge, this is the only case report in the literature of a patient with locally advanced vaginal mucosal melanoma experiencing a durable complete pathologic response and organ preservation following immune checkpoint blockade as the only treatment approach.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Front Oncol

DOI

ISSN

2234-943X

Publication Date

2022

Volume

12

Start / End Page

1044587

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tarhini, A. A., Hanayneh, W. B., Powers, J. J., Segura, C. M. M., Conejo-Garcia, J. R., Lam, C. A., … Hoffman, M. S. (2022). Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma. Front Oncol, 12, 1044587. https://doi.org/10.3389/fonc.2022.1044587
Tarhini, Ahmad A., Wissam B. Hanayneh, John J. Powers, Carlos M Moran Segura, Jose R. Conejo-Garcia, Cesar A. Lam, Ardeshir Hakam, and Mitchel S. Hoffman. “Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma.Front Oncol 12 (2022): 1044587. https://doi.org/10.3389/fonc.2022.1044587.
Tarhini AA, Hanayneh WB, Powers JJ, Segura CMM, Conejo-Garcia JR, Lam CA, et al. Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma. Front Oncol. 2022;12:1044587.
Tarhini, Ahmad A., et al. “Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma.Front Oncol, vol. 12, 2022, p. 1044587. Pubmed, doi:10.3389/fonc.2022.1044587.
Tarhini AA, Hanayneh WB, Powers JJ, Segura CMM, Conejo-Garcia JR, Lam CA, Hakam A, Hoffman MS. Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma. Front Oncol. 2022;12:1044587.

Published In

Front Oncol

DOI

ISSN

2234-943X

Publication Date

2022

Volume

12

Start / End Page

1044587

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis